Journal Mobile Options
Table of Contents
Vol. 74, No. 1-2, 2008
Issue release date: June 2008
Section title: Review
Oncology 2008;74:1–6
(DOI:10.1159/000138349)

The Promise and Perils of ‘Targeted Therapy’ of Advanced Ovarian Cancer

Markman M.
University of Texas M.D. Anderson Cancer Center, Houston, Tex., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Review

Received: 11/16/2007
Accepted: 11/16/2007
Published online: 6/9/2008

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

For several reasons, ovarian cancer is an excellent malignancy to consider the use of ‘targeted’ therapeutic strategies. However, to date, despite considerable effort, there remains limited evidence that such approaches are clinically relevant in the malignancy. The one important exception is the delivery of anti-angiogenic anti-neoplastic agents, which actually appear to be more biologically active as single drugs in ovarian cancer than in other solid tumors where they have been examined. It is anticipated that future trials of ‘targeted’ therapy in ovarian cancer will focus on molecular targets of documented relevance in the malignancy.


  

Author Contacts

Maurie Markman, MD
University of Texas M.D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030 (USA)
Tel. +1 713 745 7140, Fax +1 713 563 9586, E-Mail mmarkman@mdanderson.org

  

Article Information

Received: November 16, 2007
Accepted: November 16, 2007
Published online: June 9, 2008
Number of Print Pages : 6
Number of Figures : 0, Number of Tables : 0, Number of References : 52

  

Publication Details

Oncology (International Journal of Cancer Research and Treatment)

Vol. 74, No. 1-2, Year 2008 (Cover Date: July 2008)

Journal Editor: Markman M. (Houston, Tex.)
ISSN: 0030–2414 (Print), eISSN: 1423–0232 (Online)

For additional information: http://www.karger.com/OCL


Article / Publication Details

First-Page Preview
Abstract of Review

Received: 11/16/2007
Accepted: 11/16/2007
Published online: 6/9/2008

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.